Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Alnylam Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
LTS:0HD2'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.25 Med: -0.56 Max: 2.03
Current: 1.08
During the past 13 years, the highest Debt-to-EBITDA Ratio of Alnylam Pharmaceuticals was 2.03. The lowest was -7.25. And the median was -0.56.
LTS:0HD2's Debt-to-EBITDA is ranked better than 51.19% of 295
companies
in the Biotechnology industry
Industry Median: 1.14
vs LTS:0HD2: 1.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Alnylam Pharmaceuticals Debt-to-EBITDA Related Terms
Alnylam Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs ONC, RVMD, RPRX: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Alnylam Pharmaceuticals (LTS:0HD2) has a Debt-to-EBITDA of 1.16 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alnylam Pharmaceuticals. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #144 out of 295 companies in the Biotechnology industry, placing it in the top 48.8%.
Is Alnylam Pharmaceuticals' Debt-to-EBITDA too high?
Alnylam Pharmaceuticals' current Debt-to-EBITDA is 1.16. The Biotechnology industry median Debt-to-EBITDA is 1.14. Alnylam Pharmaceuticals' value of 1.16 is 1.8% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #144 out of 295 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Debt-to-EBITDA compare to ONC and RVMD?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #144 out of 295 companies for Debt-to-EBITDA. This puts Alnylam Pharmaceuticals in the upper half of its industry. The industry median Debt-to-EBITDA is 1.14. Alnylam Pharmaceuticals' value of 1.16 is 1.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 295 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Debt-to-EBITDA of 1.16 is 1.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alnylam Pharmaceuticals. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Debt-to-EBITDA is 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $521.88, compared to a current price of $202.64 — trading 61.2% below its estimated fair value. The current Debt-to-EBITDA is 1.16 and 1.8% above the Biotechnology industry median of 1.14. Alnylam Pharmaceuticals' overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Debt-to-EBITDA is 1.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $202.64 is trading 61.2% below its estimated GF Value™ of $521.88.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Debt-to-EBITDA: 1.16
GF Value™: $521.88 vs. price of $202.64 (61.2% below fair value)
Industry Position: 1.8% above the Biotechnology median (#144 of 295)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
62GF Score
Get the complete analysis for LTS:0HD2
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
